

Qamar J Khan

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9633041/publications.pdf>

Version: 2024-02-01

44
papers

1,890
citations

361413

20
h-index

289244

40
g-index

45
all docs

45
docs citations

45
times ranked

2709
citing authors

#	ARTICLE	IF	CITATIONS
1	Abstract P2-01-05: Impact of post-treatment ctDNA and residual cancer burden (RCB) on outcomes in patients with triple-negative breast cancer (TNBC) and residual disease. Cancer Research, 2022, 82, P2-01-05-P2-01-05.	0.9	2
2	Abstract P4-10-03: Immunogenicity of SARS-CoV-2 vaccination in subjects on active treatment for breast cancer. Cancer Research, 2022, 82, P4-10-03-P4-10-03.	0.9	0
3	Prospective longitudinal study of kinetics of humoral response to one, two, or three doses of SARS-CoV-2 vaccine in hematopoietic cell transplant recipients. Bone Marrow Transplantation, 2022, , .	2.4	4
4	Evaluation of the Durability of the Immune Humoral Response to COVID-19 Vaccines in Patients With Cancer Undergoing Treatment or Who Received a Stem Cell Transplant. JAMA Oncology, 2022, 8, 1053.	7.1	16
5	Clinical and biomarker results of neoadjuvant phase II study of pembrolizumab and carboplatin plus docetaxel in triple-negative breast cancer (TNBC) (NeoPACT).. Journal of Clinical Oncology, 2022, 40, 513-513.	1.6	36
6	Impact of low versus negative estrogen/progesterone receptor status on clinico-pathologic characteristics and survival outcomes in HER2-negative breast cancer. Npj Breast Cancer, 2022, 8, .	5.2	21
7	Randomized Phase II Trial of Anthracycline-free and Anthracycline-containing Neoadjuvant Carboplatin Chemotherapy Regimens in Stage Iâ€“III Triple-negative Breast Cancer (NeoSTOP). Clinical Cancer Research, 2021, 27, 975-982.	7.0	51
8	Clinical and Biomarker Results from Phase I/II Study of PI3K Inhibitor Alpelisib plus Nab-paclitaxel in HER2-Negative Metastatic Breast Cancer. Clinical Cancer Research, 2021, 27, 3896-3904.	7.0	36
9	Romidepsin (HDACi) plus cisplatin and nivolumab triplet combination in patients with metastatic triple negative breast cancer (mTNBC).. Journal of Clinical Oncology, 2021, 39, 1076-1076.	1.6	7
10	Serial single-cell genomics reveals convergent subclonal evolution of resistance as patients with early-stage breast cancer progress on endocrine plus CDK4/6 therapy. Nature Cancer, 2021, 2, 658-671.	13.2	34
11	Ganitumab and metformin plus standard neoadjuvant therapy in stage 2/3 breast cancer. Npj Breast Cancer, 2021, 7, 131.	5.2	13
12	Association of Event-Free and Distant Recurrenceâ€“Free Survival With Individual-Level Pathologic Complete Response in Neoadjuvant Treatment of Stages 2 and 3 Breast Cancer. JAMA Oncology, 2020, 6, 1355.	7.1	119
13	Acral vascular syndrome during an immune checkpoint inhibitor. BMJ Case Reports, 2020, 13, e233463.	0.5	4
14	Letrozole + ribociclib versus letrozole + placebo as neoadjuvant therapy for ER+ breast cancer (FELINE trial).. Journal of Clinical Oncology, 2020, 38, 505-505.	1.6	34
15	Results of randomized phase II trial of neoadjuvant carboplatin plus docetaxel or carboplatin plus paclitaxel followed by AC in stage I-III triple-negative breast cancer (NCT02413320).. Journal of Clinical Oncology, 2019, 37, 516-516.	1.6	10
16	A window of opportunity trial of atorvastatin in p53-mutant and p53 wild type malignancies.. Journal of Clinical Oncology, 2019, 37, TPS3165-TPS3165.	1.6	3
17	Fixed dose, dose-dense capecitabine in metastatic breast cancer.. Journal of Clinical Oncology, 2019, 37, e12593-e12593.	1.6	2
18	Pathological Response and Survival in Triple-Negative Breast Cancer Following Neoadjuvant Carboplatin plus Docetaxel. Clinical Cancer Research, 2018, 24, 5820-5829.	7.0	82

#	ARTICLE	IF	CITATIONS
19	Clinical and biomarker results from phase I/II study of PI3K inhibitor BYL 719 (alpelisib) plus nab-paclitaxel in HER2-negative metastatic breast cancer.. Journal of Clinical Oncology, 2018, 36, 1018-1018.	1.6	21
20	Safety of limited dose modifications for palbociclib associated neutropenia in ER+ metastatic breast cancer.. Journal of Clinical Oncology, 2018, 36, e13033-e13033.	1.6	1
21	Comparison of outcomes for AJCC 8th Anatomic and Prognostic staging in contemporary triple negative breast cancer (TNBC) multisite registry.. Journal of Clinical Oncology, 2018, 36, 555-555.	1.6	0
22	Efficacy of Neoadjuvant Carboplatin plus Docetaxel in Triple-Negative Breast Cancer: Combined Analysis of Two Cohorts. Clinical Cancer Research, 2017, 23, 649-657.	7.0	108
23	Randomized trial of vitamin D3 to prevent worsening of musculoskeletal symptoms in women with breast cancer receiving adjuvant letrozole. The VITAL trial. Breast Cancer Research and Treatment, 2017, 166, 491-500.	2.5	36
24	Clinical Activity of Pembrolizumab in a Patient With Metastatic Triple-Negative Breast Cancer Without Tumor Programmed Death-Ligand 1 Expression: A Case Report and Correlative Biomarker Analysis. JCO Precision Oncology, 2017, 1, 1-6.	3.0	2
25	Adaptive Randomization of Veliparibâ€“Carboplatin Treatment in Breast Cancer. New England Journal of Medicine, 2016, 375, 23-34.	27.0	467
26	Adaptive Randomization of Neratinib in Early Breast Cancer. New England Journal of Medicine, 2016, 375, 11-22.	27.0	301
27	Efficacy results of a phase 1b study of ONT-380, a CNS-penetrant TKI, in combination with T-DM1 in HER2+ metastatic breast cancer (MBC), including patients (pts) with brain metastases.. Journal of Clinical Oncology, 2016, 34, 513-513.	1.6	25
28	Prognosis of triple negative breast cancer patients who attain pathological complete response with neoadjuvant carboplatin/docetaxel and do not receive adjuvant anthracycline chemotherapy.. Journal of Clinical Oncology, 2016, 34, 1015-1015.	1.6	3
29	Neoadjuvant chemotherapy plus trastuzumab in stage II/III breast cancer with low HER2 expression.. Journal of Clinical Oncology, 2015, 33, 1039-1039.	1.6	1
30	Outcomes with neoadjuvant versus adjuvant chemotherapy for T1-2 node negative triple negative breast cancer.. Journal of Clinical Oncology, 2015, 33, 1092-1092.	1.6	1
31	Prognostic marker discordance between breast and axilla in patients with early breast cancer.. Journal of Clinical Oncology, 2015, 33, e11618-e11618.	1.6	3
32	Use of non-anthracycline adjuvant chemotherapy in triple-negative breast cancer: Review from a prospective registry.. Journal of Clinical Oncology, 2015, 33, e12071-e12071.	1.6	0
33	Efficacy of neoadjuvant carboplatin/docetaxel chemotherapy in sporadic and <i>BRCA</i>-associated triple-negative breast cancer (TNBC).. Journal of Clinical Oncology, 2014, 32, 1022-1022.	1.6	8
34	Chemotherapy-induced amenorrhea (CIA) risk associated with taxane/platinum-based chemotherapy in young (â‰¥45 years) breast cancer patients.. Journal of Clinical Oncology, 2014, 32, 9592-9592.	1.6	1
35	Prospective evaluation of <i>BRCA</i> mutations in a large triple-negative breast cancer (TNBC) registry: Implications for germline testing.. Journal of Clinical Oncology, 2013, 31, 1026-1026.	1.6	0
36	Randomized trial of vitamin D3 to prevent worsening of musculoskeletal symptoms and fatigue in women with breast cancer starting adjuvant letrozole: The VITAL trial.. Journal of Clinical Oncology, 2012, 30, 9000-9000.	1.6	15

#	ARTICLE	IF	CITATIONS
37	The Relationship Between Vitamin D and Breast Cancer Incidence and Natural History. <i>Current Oncology Reports</i> , 2010, 12, 136-142.	4.0	24
38	Effect of vitamin D supplementation on serum 25-hydroxy vitamin D levels, joint pain, and fatigue in women starting adjuvant letrozole treatment for breast cancer. <i>Breast Cancer Research and Treatment</i> , 2010, 119, 111-118.	2.5	173
39	Musculoskeletal Adverse Events Associated with Adjuvant Aromatase Inhibitors. <i>Journal of Oncology</i> , 2010, 2010, 1-8.	1.3	39
40	Reduction in Ki-67 in Benign Breast Tissue of High-Risk Women with the Lignan Secoisolariciresinol Diglycoside. <i>Cancer Prevention Research</i> , 2010, 3, 1342-1350.	1.5	41
41	How I Treat Vitamin D Deficiency. <i>Journal of Oncology Practice</i> , 2010, 6, 97-101.	2.5	28
42	Mammographic density does not correlate with Ki-67 expression or cytomorphology in benign breast cells obtained by random periareolar fine needle aspiration from women at high risk for breast cancer. <i>Breast Cancer Research</i> , 2007, 9, R35.	5.0	31
43	Reduction in proliferation with six months of letrozole in women on hormone replacement therapy. <i>Breast Cancer Research and Treatment</i> , 2007, 106, 75-84.	2.5	53
44	Ki-67 Expression in Benign Breast Ductal Cells Obtained by Random Periareolar Fine Needle Aspiration. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2005, 14, 786-789.	2.5	32